GBM Agile GBM AGILE Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent Glioblastoma (GBM) (Aktiv)
Erstlinie
Glio-XS15 Multi Peptide Vaccination With XS15 in Addition to Standard Postoperative Radiation Therapy and Temozolomide Chemotherapy in Newly Diagnosed Glioblastoma (Aktiv)
INTRAGO II A multicenter randomized Phase III Trial in INTraoperative RAdiotherapy in newly diagnosed GliOblastoam multiforme (INTRAGO II) (Aktiv)
PRIDE-Studie Phase-IIa-Studie zur Radiochemotherapie mit isotoxischer Dosiseskalation und schützender VEGF-Hemmung mit Bevacizumab bei Patienten mit IDH-Wildtyp und unmethyliertem MGMT-Glioblastom (Aktiv)
RESURGE Surgery for Recurrent Glioblastoma (RESURGE) (Aktiv)
TRIDENT EF-32 EF-32: Pivotal, Randomized, Open-Label Study of Optune® (Tumor Treating Fields, 200kHz) Concomitant With Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma (Aktiv)
Zweitlinie oder später
Car2Brain Intracranial Injection of NK-92/5.28.z (HER2.taNK) Cells in Patients With Recurrent HER2-positive Glioblastoma (Quilt 3.C001) (CAR2BRAIN) (Aktiv)
GIRO Phase III Studie zur erneuten Bestrahlung mit Kohlenstoffionen oder Photonen als Zweitlinientherapie bei Glioblastom (Aktiv)
HIT-HGG-Rez-Immunovac Autologous Dendritic Cells and Metronomic Cyclophosphamide for Relapsed High-Grade Gliomas in Children and Adolescents HIT-HGG-Rez-Immunovac - A Clinical Phase I/II Trial of the HIT-HGG Study Group - (Aktiv)
MecMeth Phase I/II Studie zu Meclofenamate als Zweitlinientherapie bei Glioblastom-Rezidiv mit methyliertem MGMT-Promotor (Aktiv)
PerSurge PerSurge (NOA-30) phase II trial of perampanel treatment around surgery in patients with progressive glioblastoma (Aktiv)
RESURGE Surgery for Recurrent Glioblastoma (RESURGE) (Aktiv)